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Lactobacillus plantarum DK119 as a Probiotic Confers
Protection against Influenza Virus by Modulating Innate
Immunity
Min-Kyung Park1,2, Vu NGO2, Young-Man Kwon2, Young-Tae Lee2, Sieun Yoo2, Young-Hee Cho3, SungMoon Hong3, Hye Suk Hwang2, Eun-Ju Ko2, Yu-Jin Jung2, Dae-Won Moon4, Eun-Ji Jeong4, MinChul Kim2,5, Yu-Na Lee2, Ji-Hun Jang4, Joon-Suk Oh4, Cheol-Hyun Kim3, Sang-Moo Kang2*
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Immunity & Infection, and Department of Biology, Georgia State University, Atlanta, Georgia, United States of America, 3 Department of Animal Resource Science,
Dankook University, Dandae-ro, Dongnam-gu, Cheonan-si, Chungnam, Korea, 4 Tobico Inc. Chungnam Techno Park, Jiksan-Eup, Seobuk-Gu, Cheonan-Si, Chungnam,
Korea, 5 Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, United States of America

Abstract
Lactobacillus plantarum DK119 (DK119) isolated from the fermented Korean cabbage food was used as a probiotic to
determine its antiviral effects on influenza virus. DK119 intranasal or oral administration conferred 100% protection against
subsequent lethal infection with influenza A viruses, prevented significant weight loss, and lowered lung viral loads in a
mouse model. The antiviral protective efficacy was observed in a dose and route dependent manner of DK119
administration. Mice that were treated with DK119 showed high levels of cytokines IL-12 and IFN-c in bronchoalveolar
lavage fluids, and a low degree of inflammation upon infection with influenza virus. Depletion of alveolar macrophage cells
in lungs and bronchoalveolar lavages completely abrogated the DK119-mediated protection. Modulating host innate
immunity of dendritic and macrophage cells, and cytokine production pattern appeared to be possible mechanisms by
which DK119 exhibited antiviral effects on influenza virus infection. These results indicate that DK119 can be developed as a
beneficial antiviral probiotic microorganism.
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conditions in fermented foods enables lactic acid bacteria to
survive gastric acid in the stomach and bile acid in the intestines
[12,13]. Fermented foods are a good source for isolating various
beneficial lactic acid bacterial strains. It was demonstrated that
probiotics of some lactic acid bacterial strains were able to protect
against infectious diseases [14,15], and have the anti-allergic
effects on immune diseases in mice [16,17] and humans [18,19].
Yogurt fermented with Lactobacillus was shown to reduce the cases
of catching cold in the healthy elderly [20] and to prolong the
survival periods of mice with influenza virus infection [21]. In
particular, previous studies demonstrated the protective effects on
subsequent influenza virus infection by administration of various
lactic acid bacterial strains via the oral route [22–25] or the
intranasal route [15,26–29]. In previous studies, the effects of lactic
acid bacteria on influenza include partial survival protection or
prolonged survival periods. It remains unknown whether treatments with lactic acid bacteria can confer improved protection by
reducing weight loss of infected animals and thus ameliorating
morbidity.

Introduction
Influenza is a serious respiratory disease causing over 220,000
hospitalizations and approximately 36,000 annual deaths in the
United States during seasonal epidemics [1]. Vaccination and use
of anti-influenza drugs have been undertaken worldwide. However, current vaccines are only effective if they are well matched with
the circulating influenza viruses. A recent pandemic outbreak of
the new 2009 H1N1 virus provides a good example of a limited
efficacy of current vaccination [2]. Antiviral medications also have
limitations such as immediate administration after infection,
adverse reactions, and emergence of drug resistant strains [3–7].
Thus, it is desirable to find a more general measure that would
have protective effects on influenza virus.
Probiotics are micro-organisms which bestow health benefits on
the host when administered in adequate amounts. The most
common probiotics include lactic acid bacteria. Various fermented
vegetables and dairy products contain a variety of lactic acid
bacteria that were shown to provide health benefits and
improvements to a certain level [8–11]. The capability of lactic
acid bacterial species to grow in low pH and/or high salt
PLOS ONE | www.plosone.org
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In the present study, we determined whether the Lactobacillus
plantarum DK119 (DK119) newly isolated from the fermented
vegetable food ‘‘Kimchi’’ would confer enhanced protection
against the subsequent influenza virus infection via the intranasal
or oral administration. The antiviral efficacy of DK119 was
evaluated by monitoring weight changes, and examining lung viral
loads and histology. We further tested the hypothesis that
modulating cytokine responses and innate immune cells would
play an important role in providing protection against influenza
virus by DK119 as a beneficial probiotic. Here, we also found that
alveolar macrophage cells were critically important in mediating
protection conferred by DK119.

Results
Intranasal Administration of Mice with DK119 Confers
Protection Against Lethal Infection
Respiratory tracts and lung are major tissues for influenza viral
replication. To determine the local protective effects of DK119
after local treatment, we carried out intranasal administration of
DK119 and influenza virus together. A group of mice was
intranasally infected with influenza virus only or influenza virus
mixed with DK119. Mice that were infected with the influenza
virus (2.5 LD50) and DK119 (109 CFU per mouse) showed initial
weight loss of approximately 10 to 15% but all recovered their
weights to the normal level (Fig. 1A, B). However, all mice in
DK119 untreated group were very sick as determined by their
activity and weight loss, and died or had to be euthanized after
infection with the same dose of influenza virus. The weight loss at
early time points (Fig.1A) was probably because of a high dose of
DK119 administered intranasally (109 CFU/mouse) since the
DK119 only treated control group showed a transient loss in body
weight of mice (Fig. 1). To further determine the dosage effects of
DK119 on providing protection against influenza virus, a low dose
of DK119 (108 CFU per mouse) was tested similarly (Fig. 2). The
body weight loss was found to be less at the time of day 2 post
infection compared to the high dose treatment although the
overall weigh loss was severe, resulting in over 20% loss at day 8
post infection. Also, the survival protection was observed to be
50% in the group treated with a low dose of DK119 (108 CFU/
mouse). The untreated control group showed no protection after
influenza virus infection. These results suggest that DK119
treatment has an anti-viral effect on influenza virus infection in
a dose-dependent manner.

Figure 1. Intranasal co-administration of DK119 (109 CFU) and
A/PR8 H1N1 virus confers protection. BALB/c mice (n = 5 per
group) were infected with A/PR8 virus (2.5 LD50) alone or coadministered with DK119 (109 CFU per mouse) and A/PR8 H1N1 virus,
and body weight changes were monitored daily for 14 days. Virus (V):
mice infected with A/PR8 virus, DK119(109)+V: mice infected with
DK119 and A/PR8 H1N1 virus.DK119 (109): mice treated with DK119
(109 CFU per mouse) alone. Bars indicate standard errors.
doi:10.1371/journal.pone.0075368.g001

The dose of DK119 (109 CFU/mouse) tested above appeared
to be high and use of a low dose would be desirable. To determine
whether a low dose of DK119 (108 CFU/mouse) would be
protective, mice were treated with DK119 (108 CFU/mouse) two
times at days 4 and 1 prior to lethal infection with influenza virus
(A/PR8 virus) in the presence of a10 fold low dose of DK119
(108 CFU/mouse) (Fig. 4). DK119 alone treatment did not affect
mouse body weight changes (Fig. 4). All mice with intranasal
DK119 pretreatment were 100% protected against lethal infection
of influenza virus only a moderate level of body weight loss (6–9%
loss) at day 6–7 post infection (Fig. 4). In support of our hypothesis,
the pretreatment with DK119 prior to infection showed improved
protection by preventing substantial weight loss even at the low
dose of DK119 (108 CFU/mouse) compared to the severe weight
loss observed in mice infected with influenza virus and the same
dose of DK119 (Fig. 2).

Effects of Pretreatment of Mice with DK119 on Influenza
Virus Infection
Pretreatment of mice with other lactic acid bacteria was shown
to provide survival benefits after influenza virus infection [15,29].
Therefore, we hypothesized that pretreatment with DK119 would
improve the protective efficacy. Mice were once treated with a low
dose of DK119 (107 CFU/mouse) 4 days earlier prior to infection.
Then, mice were infected with a lethal dose of influenza virus in
the presence of DK119 (109 CFU/mouse) (Fig. 3). All mice with
intranasal pre-treatment of DK119 showed only minimum (,5–
7%) loss of weight and survived the lethal infection, indicating that
protection by DK119 treatment was significantly improved. It is
also important to note that pretreatment with a low dose of
DK119 (107 CFU/mouse, Fig. 3) prevented even the transient loss
of body weight that was observed after high dose treatment with
DK119 alone (109 CFU/mouse, Fig. 1). Therefore, pretreatment
with DK119 prior to infection significantly improved protection
against influenza virus (Fig. 3).
PLOS ONE | www.plosone.org

Effects of Oral Administration with DK119 on Influenza
Virus Infection
Fermented foods that contain DK119 are orally consumed in
humans, and thus the effects of oral administration with DK119
would be a more appropriate route to be tested. Mice (n = 6 per
group) were orally administered DK119 (109 CFU/mouse) daily
for 10 days prior to infection with influenza virus. After infection
with influenza H1N1 virus (A/PR8, 2.5 LD50), DK119 oral
administration daily was continued for 14 days. Untreated mice
showed over 25% weight loss and had to be euthanized (Fig. 5).
The DK119 treated group showed a moderate weight loss
approximately 14% at peak and then 100% mice survived. A
lower dose of DK119 (108 CFU/mouse) via oral administration
also conferred 100% survival protection against a low dose (1
LD50) of influenza A/PR8 virus infection (Fig. 6). These results
2
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Figure 2. Intranasal co-administration of a low dose of DK119 (108 CFU) and A/PR8 virus (H1N1) provides survival protection. BALB/
c mice (n = 6 per group) were infected once with A/PR8 virus (2.5 LD50) alone or co-administered with DK119 (108 CFU per mouse) and A/PR8 virus,
and monitored daily for 14 days. Virus(V): mice infected with A/PR8 virus, DK119 (108)+V: mice infected with DK119 and A/PR8 virus.DK119 (108): mice
treated with DK119 (108 CFU per mouse) alone did not show weight losses.
doi:10.1371/journal.pone.0075368.g002

indicate that DK119 oral administration provides beneficial effects
on protecting influenza virus infection in spite of a certain degree
of morbidity.

effects by DK119 treatment, cytokine levels were determined in
bronchoalveolar lavage fluids (BALF) at day 4 post infection.
DK119 treated mice (108, 109, Fig. 8) showed low levels of
cytokines compared to the virus infected mice without DK119
pretreatment. Levels of cytokines IFN-c and IL-12 were found to
be elevated in BALF from mice orally or intranasally treated with
DK119 compared to those from mice that were infected with
influenza virus without DK119 (Fig 8D, E). The DK119
intranasally administered group (108+V, Fig. 8) showed the
highest level of IL-12 and lower levels of IL-4 and IL-6 cytokines.
In particular, IFN-c was also found to be high in sera and lung
extracts from DK119 treated mice upon influenza virus infection
(data not shown). In contrast, cytokines IL-4, IL-6, TNF-a were
detected at lower levels in BALF from mice with DK119 treatment
compared to those from mice that were infected with influenza
virus without DK119 (Fig. 8). Consistent with the pattern of
inflammatory cytokines, a high degree of inflammation was
observed in the peribronchial and perivascular alveolar lung
tissues from influenza virus infected mice but not from mice with
intranasal DK119 pretreatment (Fig. 9). Therefore, it is speculated
that DK119 treatment enhances innate immune responses
stimulating the production of T helper 1 type (Th1) anti-viral
cytokines (IFN-c, IL-12) and suppressing Th2 like or inflammatory
cytokines (IL-4, IL-6, TNF-a) responses.

DK119 Treatment Lowers Lung Viral Loads after Influenza
Infection
Viral loads in the lungs provide important information for
assessing the efficacy of protection against influenza virus infection.
At day 4 post infection with H1N1 influenza virus, lung samples
were collected and viral titers were determined as an egg infectious
dose (Fig. 7). Lung viral load was detected at a high level in mice
with influenza virus infection in the untreated control (Fig. 7).
DK119 oral administration (109 CFU/mouse) or intranasal
treatment (108 CFU/mouse) resulted in a reduction of lung viral
loads by approximately 200 to 800 fold (Fig. 7). Interestingly, lung
viral load was significantly reduced to more than a 4 log lower
level in the group of mice that were intranasally treated with a
high dose DK119 (109 CFU/mouse) during infection compared to
that in the untreated control group (Fig. 7). Therefore, DK119
oral or intranasal administration can reduce lung viral loads in
mice after influenza virus infection.

DK119 Treatment Increases the Production of Cytokines
IFN-c and IL-12
Inflammatory cytokines are known to be associated with severe
lung disease and high mortality. To better understand beneficial
PLOS ONE | www.plosone.org
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Figure 4. Effects of DK119 (108 CFU) treatment on preventing
weight loss against influenza H1N1 virus infection. A group of
mice (n = 6) was treated with DK119 (108 CFU/mouse) at 4 days and 1
day prior to infection with A/PR8 virus (2.5 LD50) in the presence of a
low dose of DK119 (108 CFU per mouse). Virus(V): mice infected with A/
PR8 virus, DK119 (108+108+108)+V: mice pretreated twice with DK119
and infected A/PR8 H1N1 virus in the presence of with DK119 (108 CFU
per mouse). Bars indicate standard errors.DK119 (108+108+108): mice
treated with DK119 alone (108 CFU/mouse at 3 different time points
without virus infection).
doi:10.1371/journal.pone.0075368.g004

Figure 3. Pretreatment of a low dose of DK119(107 CFU)
confers improved protection by preventing severe weight
loss. A group of mice (n = 6) was once treated intranasally with a low
dose of DK119 (107 CFU per mouse). After 4 days of DK119 treatment,
mice were infected with A/PR8 H1N1 virus (2.5 LD50) in the presence of
DK119 (109 CFU per mouse). The control group was infected with A/PR8
virus without DK119 and no pretreatment. Virus(V): mice infected with
A/PR8 H1N1 virus, DK119(107+109)+V: mice pretreated with DK119 and
infected with DK119 and A/PR8 H1N1 virus.DK119(107+109): mice
treated with DK119 (107 CFU and 109 CFU per mouse). Bars indicate
standard errors.
doi:10.1371/journal.pone.0075368.g003

protection, DK119 treated mice with or without clodronateliposome administration were infected with a lethal dose of mouseadapted influenza A/Philippines/82 H3N2 virus (Fig. 12).DK119
alone treatment even in the administration of clodronate did not
affect mouse body weight changes. More importantly, all mice in
DK119 treated group without clodronate survived lethal infection
and did not exhibit weight loss. It is worth to note that DK119
pretreatment could provide good protection against H3N2
influenza virus. The group of DK119 treated mice that received
intranasal administration of clodronate showed severe weight loss
and did not show any protection (Fig. 12). These results indicate
that alveolar macrophage cells play a critically important role in
DK119-mediated protection. In addition, DK119 pretreatment
can provide protection against A/Philippines/82 (H3N2) virus,
which is similar to the protection against A/PR8 (H1N1) virus.

Depletion of Dendritic and Macrophage Cells Abolishes
Protection Mediated by DK119 Treatment
For better understanding the effects of DK119 on improving
protection, bone marrow derived dendritic cells (BMDCs) were
treated with DK119 and analyzed by flow cytometry (Fig. 10).
DK119 treatment on BMDCs resulted in increases of CD11c+
populations by 2 to 2.5 fold (Fig. 10). Therefore, increases in
dendritic cell populations by DK119 might be contributing to
improving the protection against influenza virus infection.
Since alveolar macrophages were reported to contribute to
controlling lung viral loads and reducing mortality [30], we further
hypothesized that lung airway dendritic and macrophage cells
would play a vital role in conferring DK119-mediated protection
against influenza virus. It was previously reported that dendritic
and macrophage cells were selectively depleted by intranasal or
intratracheal administration with clodronate-liposomes [31,32].
F4/80+CD11c+CD11b2 phenotypic cells were classified as alveolar macrophages in a study of infected lungs [33]. We found that
intranasal administration of clodronate-liposomes resulted in
significant depletion of CD32CD11b2CD11c+F4/80+ phenotypic
alveolar macrophage cells in the lungs (Fig. 11). The percentages
(Fig. 11B) and cellularity (Fig. 11C) of CD11c+F4/80+ phenotypic
alveolar macrophage cells were found to be depleted by
approximately 80% in bronchoalveolar lavages and lungs.
A group of mice was treated with DK119 probiotic at a low
dose (108 CFU/mouse). To determine the effects of the selective
depletion of dendritic and macrophage cells on DK119-mediated
PLOS ONE | www.plosone.org

Discussion
This study reports that Lactobacillus plantarum DK119 has
significant antiviral effects on influenza virus infection via
intranasal or oral administration, conferring survival protection
as well as preventing substantial weight loss. In previous studies
reporting antiviral protection, mice treated with different strains of
Lactobacillus exhibited prolonged survival periods without protection [22,23] or were only partially protected after lethal infection
[25–27], but illness has not been reported. It was recently
demonstrated that various Lactobacillus species showed differential
protective efficacies with a wide range of 0–100% survival rates
against influenza virus infection depending on administration
routes and doses [15]. Thus, in this study, we report substantial
antiviral activity of DK119, preventing illness as indicated by
4
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Figure 5. Oral administration of DK119 (109 CFU) has protective effects against influenza virus infection. Mice (n = 5) were
administered DK119 (109 CFU/mouse daily) orally for 10 days before
infection and for 14 days after infection with A/PR8 H1N1 virus (2.5
LD50), and their body weight changes were recorded. Virus(V): A/PR8
virus infection, DK119(109)+V: Oral administration with DK119 and then
virus infection. Bars indicate standard errors. DK119(109): mice treated
orally with DK119 alone (109 CFU/mouse daily for 14 days).
doi:10.1371/journal.pone.0075368.g005

Figure 6. Oral administration of mice with a low dose of DK119
has protective effects against influenza virus (H1N1) infection.
Mice (n = 6) were orally administered DK119 (108 CFU/mouse daily) for
10 days before infection and for 14 days after infection with A/PR8 virus
(1 LD50). Body weight changes were recorded. Virus(V): A/PR8 virus
infection, DK119 (108)+V: Oral administration with DK119 and virus
infection.
doi:10.1371/journal.pone.0075368.g006

diminishing weight losses in mice after lethal infection with
influenza viruses as well as conferring 100% survival protection
against H1N1 and H3N2 influenza A viruses.
In contrast to most previous studies reporting only survival rates
[22,23,25–27], we determined body weight changes as an
important measure of illness, which should be considered for
evaluating the protective efficacy. Results in this study suggest that
intranasal treatment with low doses of DK119 prior to influenza
virus infection significantly improves protection by preventing
severe weight losses. Also, the protective efficacy against influenza
virus infection was observed in a DK119 dose-dependent manner.
Another important parameter in evaluating protective efficacy is a
magnitude of controlling lung viral loads. Intranasal or oral
treatment of mice with DK119 lowered lung viral titers by 200 to
10000 fold. The efficacy of lowering lung viral titers was
dependent on doses and routes of DK119 treatments. Although
direct comparison is not possible, previous studies reported
approximately 10 to 20 fold decreases in lung viral titers at the
day 2–3 post infection [15,22,23,28]. Therefore, it is assumed that
DK119 strain as a novel strain of Lactobacillus tested in this study
might have potent antiviral activity against influenza virus.
Pathogenesis of influenza virus infection is known to be involved
with hyper-inflammatory responses [30,34–36]. In particular,
levels of cytokines IL-6 and TNF-a were reported to be positively
correlated with influenza associated lethality [35,37]. In this study,
mice that were infected with influenza A/PR8 virus showed high
levels of inflammatory cytokines, IL-4, IL-6, TNF-a, but low levels
of IFN-c and IL-12. In contrast, DK119 treatment of mice
resulted in a reverse pattern of cytokines, increasing the levels of
IFN-c, IL-12,and decreasing inflammatory cytokines (IL-4, IL-6,

PLOS ONE | www.plosone.org

Figure 7. DK119 pretreatment promotes lung viral clearance
after influenza virus infection. Lung viral titers at day 4 post
infection with H1N1 influenza virus A/PR8 are determined and
presented in log10 units of limiting dilutions showing viral replication
in chicken eggs. (10̂8)+V: mice intranasally pretreated with DK119
(108 CFU) and infected with A/PR8 virus in the presence of DK119 (108).
(10̂9)+V: mice intranasally pretreated with DK119 (107 CFU) and
infected with A/PR8 virus in the presence of DK119 (109). DK119
(oral)+V: mice orally pretreated with DK119 (109 CFU) for 10 days and
then infected with A/PR8 virus. Virus: Naı̈ve mice infected with A/PR8
virus (2.5 LD50). * (p,0.05), ** (p,0.001) statistical significances are
indicated. Bars indicate standard errors.
doi:10.1371/journal.pone.0075368.g007
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Figure 8. Effects of DK119 pretreatment on cytokine production upon influenza virus infection. Levels of cytokines in bronchoalveolar
lavage fluids (BALF) collected from mice (n = 3) at day 4 post infection with A/PR8 virus are presented in pg/ml as determined using cytokine ELISA.
(A) IL-4, (B) IL-6, (C) TNF-a, (D) IL-12, (E) IFN-c. DK119 (10̂8): Intranasal DK119 10̂8 control in the absence of A/PR8 virus infection. DK119 (10̂9):
Intranasal DK119 10̂9 control in the absence of A/PR8 virus infection. (10̂7)+V: DK119 (10̂7) intranasal pretreatment and then A/PR8 virus infection in
the presence of DK119 (10̂9). (10̂8)+V: DK119 (10̂8) intranasal pretreatment and then A/PR8 virus infection in the presence of DK119 (10̂9). Virus: Naı̈ve
mice infected with A/PR8 virus (2.5 LD50). * indicates statistical significance compared to the control virus group (p,0.05). Bars indicate standard
errors.
doi:10.1371/journal.pone.0075368.g008

neutrophils, and natural killer cells would be the candidate cells
[30]. Innate immunity is the first defense host mechanism in
responding to pathogens. Thus, modulating innate immunity
would be a mechanism for DK119-mediated protection against
influenza. However, detailed mechanisms remain to be determined.
Macrophage and dendritic cells (DCs) play important roles in
activating innate and adaptive immune systems by their initial
responses to environmental microorganisms. We found that
protection conferred by DK119 treatment was completely

TNF-a). In particular, IFN-c was prominently detected in BALF,
lung extracts, and sera from DK119-treated mice. Consistent with
results in this study, oral administration of Lactobacillus plantarum
strain was shown to enhance the production of Th1 type cytokine
IFN-c in response to ovalbumin immunization [38]. Similarly,
intranasal administration of Lactobacillus pentosus strain was
previously reported to induce Th1 like cytokines IL-12 and IFNc possibly contributing to host resistance to influenza infection
[28]. Although the source of cytokine producers is not clear in this
study, innate immune cells such as macrophages, dendritic cells,

Figure 9. DK119 pretreatment reduces influenza virus-induced lung histopathology. Inflammatory histopathology after H&E staining of
lung sections was compared from mice that were infected with influenza A/PR8 virus (H1N1) with or without DK119 treatment. (A) Naı̈ve: Naı̈ve mice
without A/PR8 virus and DK119, (B) Virus: mice that were infected with A/PR8 virus without DK119 treatment, (C) DK119+Virus: DK119 (107) intranasal
pretreatment and then A/PR8 virus infection in the presence of DK119 (109). All images were obtained using the same camera setting and shown at a
magnification of X400.
doi:10.1371/journal.pone.0075368.g009

PLOS ONE | www.plosone.org
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a promising strain as probiotics because it showed tolerance to acid
and bile salt [41]. DK119 was cultured in MRS broth (Difco,
Detroit, MI) at 37uC for 24 h. Cultured DK119 were harvested by
centrifugation at 10,000 rpm at 4uC for 10 minutes, washed twice
with phosphate-buffered saline (PBS), and suspended in saline for
the following experiments. DK119 colony forming units (CFU)
were determined by counting colonies on the MRS agar plates.
Mouse adapted influenza virus strains A/Puerto Rico/8/1934
(H1N1; A/PR8) and A/Philippines/82 (H3N2 subtype) were
grown in embryonated hen’s eggs as described [42–45] and used
in this study to infect mice.

Figure 10. DK119 increases CD11c+ cell populations from
BMDCs. Bone marrow derived dendritic cells (BMDCs) were seeded in
concentrations of 2.56105 cells/ml and treated with 56106 CFU/ml of
DK119 or 2.56108 CFU/ml for 2 days. The cells within a circle are CD11c
positive cells and their percentages indicated. A representative figure in
each is shown from three independent experiments. Control: No DK119,
DK119 (20): 56106 CFU/ml of DK119, DK119 (1000): 2.56108 CFU/ml of
DK119.
doi:10.1371/journal.pone.0075368.g010

Treatment of Mice with DK119 and Influenza Virus A/PR8
Female BALB/c mice (6–8 weeks old, Harlan Laboratories)
were used (n = 5–6 each group). For oral administration of
DK119, mice received intra-gastric administration of 200 ml of
suspension containing 109 or 108 CFU of live DK119 once daily
for consecutive 10 days via a feeding needle. At the 10th day of
DK119 oral treatment, mice were infected with 50 ml of influenza
virus A/PR8 virus (2.5 LD50, 50% lethal dose for BALB/c mice)
as described [42–45]. Oral administration was continued until 14
days after infection, and body weight changes and survival rates
were monitored daily for 2 weeks. A control group was infected
with the same dose of A/PR8 virus without DK119 probiotic. For
intranasal treatment, mice were anesthetized with isoflurane using
an oxygen controlled machine (Baxter, Deerfield, IL) and then
administered DK119 (109, 108, or 107 CFU per mouse) and A/
PR8 H1N1 virus (2.5 LD50) or A/Philippines/82 H3N2 virus (2
LD50). All animals that were infected with virus were daily
monitored, and their weight and survival rates were recorded. The
humane endpoint for survival studies is 25% loss in body weights
and mice were humanely euthanized to avoid severe illness.
Animal experiments presented in this study were approved by the
Georgia State University IACUC review boards (IACUC
A11026). All animal experiments and husbandry have been
carried out under the guidelines of the Georgia State University
IACUC. Georgia State University IACUC operates under the
federal Animal Welfare Law (administered by the USDA) and
regulations of the Department of Health and Human Services.

abolished when alveolar macrophage cells (CD11c+F4/80+) were
depleted in these mice prior to infection with influenza A/
Philippines/82 H3N2 subtype virus (Fig. 12). Naı̈ve mice that were
infected with the same dose and virus were not protected in the
absence of DK119 treatment regardless of clodronate-mediated
depletion of alveolar macrophages (Fig. 12). Therefore, it is
speculated that DK119 treatment modulates alveolar macrophages and probably dendritic cells in a way for promoting protective
host innate immunity to influenza infection. Also, we found
thatDK119 induced the substantial expansion of CD11c+cells of
BMDCs in vitro. In support of this hypothesis, neutrophils and
alveolar macrophage cells were reported to play an important role
in controlling influenza virus replication and enhancing survival of
infected mice [30]. It was also reported that Lactobacillus stimulated
human dendritic cells to secrete Th1/Th17 cytokines including
IL-12 [39]. Lactobacillus was also shown to induce the production of
Th1 polarizing cytokine IL-12 by stimulating murine dendritic
cells via Toll-like receptor-2-dependent mechanism [40]. There is
a possibility that the capability of DK119 to induce IL-12 and
IFN-c cytokines in innate immune cells such as dendritic,
macrophage cells, and neutrophils subsequently contributes to
improving an anti-viral immunity of the host. Further studies
remain to be performed as a future direction to better understand
the DK119-mediated protection against influenza.
In conclusion, administration of DK119 provided protection
against infection with H1N1 and H3N2 influenza viruses,
probably by enhancing the innate immunity of CD11c+ dendritic
and macrophage cells and anti-viral cytokines, and thus contributing to better controlling of lung viral loads. DK119 is orally
consumed in humans through various fermented cabbage foods
and various forms of commercial food products. There might be
some concerns about the safety of using DK119 via the intranasal
route although apparent adverse effects were not observed in mice
with low doses of DK119 (107–108 CFU) pretreatment intranasally. Histology data in this study indicated that intranasal
pretreatment with DK119 almost prevented virus-induced lung
inflammation (Fig. 9). These results in this study support evidence
that further studies on the use of DK119 as a beneficial probiotic
will be important.

Lung Viral Titers and Cytokine Assays
To collect lung samples, mice were killed at day 4 post infection
with A/PR8 virus, and bronchoalveolar lavage fluids (BALF) and
lung samples were collected from individual mice as described
[43–45]. Lung extracts were prepared using a mechanical tissue
grinder with 1.5 ml of PBS per each lung and egg-infectious viral
titers were determined by hemagglutination activity assay in the
10-day-old embryonated chicken eggs [46]. Levels of cytokines in
BALF were determined by cytokine ELISA as described [42–45],
and Ready-Set-Go IL-4, IL-6, IL-12, TNF-a, IFN-c cytokine kits
(eBioscience, San Diego, CA) were used following the manufacturer’s procedure.

Treatment of Mice with Clodronate-liposomes and Flow
Cytometry
Liposome-encapsulated clodronate liposomes (Foundation Clodronateliposomes.com, The Netherlands) were prepared as
previously described [47]. Four hours prior to infection with
influenza virus A/Philippines/82 (H3N2), a group of DK119treated mice (n = 6 BALB/c) was intranasally administered
clodronate-liposomes (100 ml per mouse) to deplete dendritic
and macrophage cells [31,32,48]. Clodronate was a kind gift of
Roche Diagnostics GmbH, Mannheim, Germany. To determine

Materials and Methods
Preparation of Lactobacillus plantarum DK119 and Virus
Lactobacillus plantarum strain DK119 (DK119) isolated from
Korean fermented vegetable food ‘‘Kimchi’’ was previously
described [41]. Lactobacillus plantarum DK119 was suggested to be
PLOS ONE | www.plosone.org
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Figure 11. Intranasal administration of clodronate-liposomes selectively depletes CD11c+F4/80+alveolar macrophages in lungs and
bronchoalveolar lavages. The cells from the bronchoalveolar lavage (BAL) and lungs from mice (n = 3) were harvested4 days after clodronate
injection. CD3+ and CD11b+ cells were excluded to determine the effect of clodronate on depleting alveolar macrophages with
CD32CD11b2CD11c+F4/80+markers. (A) Representative profiles of flow cytometry gating of CD32CD11b2CD11c+F4/80+phenotypic cells. (B)
Percentages of CD32CD11b2CD11c+F4/80+cells. (C) Cellularity of CD32CD11b2CD11c+F4/80+cells. (2) Clodronate or (2)Clod: No clodronate control
mice, (+) Clodronate or (+)Clod: Clodronate treated mice. BAL: Bronchoalveolar cells, Lung: Cells collected from lung tissues. *P,0.05, **P,0.001,
***P,0.0001 (Student T-test). Bars indicate standard errors.
doi:10.1371/journal.pone.0075368.g011

Finally, sectioned lung tissues were stained with hematoxylin and
eosin and then examined under the microscope as described [49–
51].

the efficacy of alveolar macrophage depletion, lung and bronchoalveolar cells were obtained at day 4 post treatment with
clodronate and stained with surface marker antibodies (CD45,
CD3, F4/80, CD11b, CD11c). All flow cytometry antibodies were
purchased from BD Biosciences or eBiosciences. Stained cells were
acquired by flow cytometer LSRFortessa (BD Biosciences) and
analyzed using the FlowJo program (Tree Star Inc.) to confirm the
phenotypes of cells depleted.

Bone Marrow Derived Dendritic Cell (BMDC) Preparation
Dendritic cells (BMDCs) were generated from bone marrow of
BALB/c mice [52–54]. Briefly, the harvested cells from femur and
tibia bones were seeded onto 6-well culture plates and incubated in
the presence of granulocytes-macrophages colony stimulation
factor (10 ng/ml). BMDCs (2.56105 cells/ml) were treated with
live DK119, harvested after 2 days’ incubation, and stained with
CD11c dendritic cell marker antibody.

Histology
Lung samples were collected after blood taken via the
abdominal aorta, fixed in 10% neutral buffered formalin for
48 hrs, transferred to 70% ethanol, and embedded in paraffin.
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Figure 12. Effects of clodronate treatment on DK119-mediated protection against H3N2 influenza virus infection. Groups of mice
(n = 6) were two times treated with DK119 (108 CFU/mouse) at 4 and 1 day earlier, then either received clodronate or PBS 4 hours prior to infection
with A/Philippines/82H3N2 virus (2.5 LD50) in the presence of a low dose of DK119 (108 CFU per mouse). DK119+H3N2: mice pretreated with DK119
were infected with A/Philippines/82 (H3N2) virus. DK119+clodronate+H3N2: mice pretreated with DK119 were intranasally administered clodronate
prior to infection with A/Philippines/82 (H3N2) virus. H3N2+Clodronate: mice treated with clodronate 4 hours prior to infection.DK119+Clodronate:
mice treated with DK119 at the same doses and then clodronate administration. Bars indicate standard errors.
doi:10.1371/journal.pone.0075368.g012

Statistical Analysis

Author Contributions

To determine the statistical significance among multiple groups,
an ANOVA test was used in the GraphPad Prism program
whereas a two-tailed Student’s t-test was used when comparing
two different conditions. A p value less than 0.05 was considered to
be significant.
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